A bipartisan group of four U.S. House members sent a letter August 18 to President Trump and three cabinet officials asking for detailed guidance on how the administration's Schedule III marijuana framework will work in practice, and gave the administration until September 30 to respond. That deadline is now roughly two weeks away, and as of publication, the questions remain unanswered.
Reps. Dina Titus (D-Nev.), Dave Joyce (R-Ohio), Ilhan Omar (D-Minn.) and Greg Steube (R-Fla.) sent their letter August 18 to President Trump, Attorney General Todd Blanche, HHS Secretary Robert F. Kennedy Jr. and Treasury Secretary Scott Bessent, requesting responses by September 30. As of this article's publication date, no public response has been issued.
What the Letter Asks
The administration moved state-licensed medical marijuana to Schedule III on April 23, with Attorney General Blanche signing the order under authority tied to an international narcotics treaty. Five months later, the bipartisan lawmakers say core implementation questions remain unresolved, and their letter poses five specific requests for guidance:
How the rescheduling order affects existing state medical marijuana patients and home cultivation rights; whether the Justice Department will coordinate with Medicare and Medicaid on coverage for Schedule III cannabis products; how the framework applies to companies operating in both medical and adult-use markets, including whether they can receive Section 280E federal tax relief for their medical operations while continuing to sell recreational marijuana; how DEA registration will affect federal enforcement against businesses and patients who are not registered; and what information the DEA will require for registration, along with what privacy protections will apply to that data.
The DEA has opened a registration portal, and applicants who submitted by June 26 qualify for expedited six-month review. But practical guidance from HHS, Treasury and DOJ on the questions above has not yet been issued, which is what prompted the lawmakers' letter.
Why It Matters
Rescheduling marijuana to Schedule III was a significant regulatory shift, but shifting a drug's schedule does not, on its own, answer basic operational questions that patients, state-licensed businesses and tax authorities need answered: Can a dual medical-and-adult-use operator claim 280E relief on part of its business? Will federal healthcare programs treat Schedule III cannabis products differently than they treated Schedule I marijuana? What happens to a patient who grows at home under a state medical program but hasn't registered with the DEA? Five months after the order took effect, those questions still do not have clear public answers, which creates uncertainty for exactly the state-licensed businesses and patients the rescheduling order was meant to benefit.
A bipartisan letter with a public deadline raises the political cost of continued silence, but it does not compel a response. If the administration misses September 30, there is no automatic enforcement mechanism forcing an answer, though the letter positions lawmakers to push further, including potentially through hearings or additional legislative pressure.
What Happens Next
If the administration responds by September 30, the answers will likely shape how state-licensed operators approach tax filings, banking relationships and registration timelines. If the deadline passes without a response, expect continued pressure from Capitol Hill, and continued uncertainty for patients and businesses trying to plan around a rescheduling order whose practical mechanics are still not fully defined five months after it took effect.
What This Means for Texas
Texas's Compassionate Use Program operates under state law separate from the federal Schedule III framework, and federal guidance on DEA registration, Medicare coverage or 280E relief for dual-license operators has limited direct bearing on Texas's more narrowly defined medical cannabis program. Texas hemp-derived product rules are governed by a separate framework entirely. Texas patients and operators should treat this federal guidance process as background context rather than something that changes Texas law today. See our coverage of the D.C. Circuit's rejection of a stay in the broader rescheduling litigation for how the legal fight over Schedule III is unfolding elsewhere.
The Bottom Line
Four bipartisan House members gave the Trump administration until September 30 to explain how Schedule III marijuana rules affect patients, DEA registration, Medicare coverage and business tax treatment. The deadline is about two weeks away, and as of publication, the administration has not issued public guidance answering those questions. Whether the administration responds on time, and what it says if it does, will shape how state-licensed cannabis operators and patients navigate a rescheduling order whose practical details remain unsettled five months after taking effect.